TY - JOUR
T1 - Accelerated neoadjuvant chemotherapy of non-small cell lung cancer (NSCLC)
AU - Lorusso, Vito
AU - Carpagnano, Francesco
AU - Di Rienzo, Gaetano
AU - Catino, Annamaria
AU - Cisternino, Marco Luigi
AU - Guida, Michele
AU - Brandi, Mario
AU - Latorre, Agnese
AU - Parisi, Salvatore
AU - Ricco, Rosa
AU - De Lena, Mario
PY - 1996/4
Y1 - 1996/4
N2 - Thirty patients with marginally resectable stage IIIA or stage IIIB NSCLC were treated with cisplatin (80 mg/m2/i.v./dl), ifosfamide (4,000 mg/m2/i.v./dl) and vinorelbine (30 mg/m2/i.v./dl) plus G-CSF 300 μg/s.c. on days 7-12 every 14 days for three cycles before surgery. In 26 evaluable patients, the radiographically assessed response rate to chemotherapy was 77% (8% complete). Three septic deaths (10%) occurred in spite of G-CSF and 1 patient refused to continue after the first cycle. Thoracotomy was performed in 23 patients including 19 complete resections. At 15 months median follow-up (range 10-22+), 11/19 (57%) completely resected patients relapsed. The overall median time to treatment failure was 11 months (range 0-17). Actuarial survival probability at 12, 18 and 24 months are 56%, 43% and 36%, respectively. In conclusion, the combination of cisplatin, ifosfamide and vinorelbine in full doses at a 14 day interval (accelerated chemotherapy) was very effective in neoadjuvant NSCLC setting. Nevertheless, relevant toxicity was demonstrated with a 10% death rate probably due to the overlapping toxicity of chemotherapy cycles, suggesting the need for a more intense supportive care or longer interval between cycles.
AB - Thirty patients with marginally resectable stage IIIA or stage IIIB NSCLC were treated with cisplatin (80 mg/m2/i.v./dl), ifosfamide (4,000 mg/m2/i.v./dl) and vinorelbine (30 mg/m2/i.v./dl) plus G-CSF 300 μg/s.c. on days 7-12 every 14 days for three cycles before surgery. In 26 evaluable patients, the radiographically assessed response rate to chemotherapy was 77% (8% complete). Three septic deaths (10%) occurred in spite of G-CSF and 1 patient refused to continue after the first cycle. Thoracotomy was performed in 23 patients including 19 complete resections. At 15 months median follow-up (range 10-22+), 11/19 (57%) completely resected patients relapsed. The overall median time to treatment failure was 11 months (range 0-17). Actuarial survival probability at 12, 18 and 24 months are 56%, 43% and 36%, respectively. In conclusion, the combination of cisplatin, ifosfamide and vinorelbine in full doses at a 14 day interval (accelerated chemotherapy) was very effective in neoadjuvant NSCLC setting. Nevertheless, relevant toxicity was demonstrated with a 10% death rate probably due to the overlapping toxicity of chemotherapy cycles, suggesting the need for a more intense supportive care or longer interval between cycles.
KW - Lung cancer
KW - Preoperative chemotherapy
KW - Surgery
UR - http://www.scopus.com/inward/record.url?scp=0029881153&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0029881153&partnerID=8YFLogxK
M3 - Article
C2 - 21544412
AN - SCOPUS:0029881153
VL - 8
SP - 675
EP - 680
JO - International Journal of Oncology
JF - International Journal of Oncology
SN - 1019-6439
IS - 4
ER -